We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Apple, ExxonMobil, Citigroup and Amgen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (AAPL - Free Report) , ExxonMobil (XOM - Free Report) , Citigroup (C - Free Report) and Amgen (AMGN - Free Report) .
Top Analyst Reports for Apple, ExxonMobil, Citigroup and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Apple, ExxonMobil, Citigroup and Amgen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Apple’s shares have gained +20.5% over the last year and have outperformed the broader market with the S&P 500 gaining +10.2% over the same period. Apple’s second-quarter fiscal 2018 results benefited from growth in iPhone and Services segment.
The Services segment on the back of growing Apple Music & Apple Pay has become the new cash cow for the company. The higher ASP of iPhone X is boosting the top-line growth. Demand in China rebounded strongly driven by iPhone, Services, Mac and Watch sales.
Going forward, the Zacks analyst thinks Apple’s foray into fast-growing technologies like autonomous vehicle, artificial intelligence (AI) & AR/VR will drive growth. However, Apple faces significant competition in most of its operating markets. The rise of feature-rich regional smartphones at a much cheaper price remains a major headwind.
Shares of ExxonMobil have underperformed the Zacks Integrated Oil industry (-5.9% vs. +18.2%) as well as peer Chevron (+19.7%) over the last year. Exxon Mobil has a leading position in the energy industry owing to the size and diversity of its asset base, both in terms of business mix and geographical footprint. With a stable cash position, the company’s balance sheet is one of the best in the industry.
This has allowed Exxon to reward stockholders with 6.3% average annual dividend hike over the past 35 years. The Zacks analyst is optimistic about Canada’s Hebron project as the oil field has been backing Exxon’s upstream operations.
The company’s cost-control initiatives are impressive as reflected from 60% sequential reduction in exploration costs through first-quarter 2018. However, the company’s first-quarter earnings were lower than expected, thanks to decreased refinery throughput and lower margins at the chemical business.
Citigroup’s shares have underperformed the Zacks Major Banks industry over the last six months, losing -7.8% vs +1.3%. However, the company possesses an impressive earnings surprise history, beating expectations in all the trailing four quarters. The company’s first-quarter 2018 earnings reflected high revenues, along with loan growth. However, expenses escalated on ongoing investments.
The Zacks analyst thinks the company’s restructuring and streamlining efforts, strategic investments in core business, lower tax rate and expense management will likely support profitability. Expansion of wealth-management business in Australia will act as a tailwind.
Yet several issues, including litigation burden, keep us apprehensive. Also, despite rising rates, margin remains under pressure, due to persistent decline in the company’s legacy holdings portfolio.
Shares of Amgen have lost -2.6% year to date, outperforming the Zacks Biomedical and Genetics industry, which has declined -12% over the same period. Amgen beat expectations for both earnings and sales in 2018. Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Vectibix, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year.
However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands.
While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Apple, ExxonMobil, Citigroup and Amgen
For Immediate Release
Chicago, IL – May 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (AAPL - Free Report) , ExxonMobil (XOM - Free Report) , Citigroup (C - Free Report) and Amgen (AMGN - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Apple, ExxonMobil, Citigroup and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Apple, ExxonMobil, Citigroup and Amgen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Apple’s shares have gained +20.5% over the last year and have outperformed the broader market with the S&P 500 gaining +10.2% over the same period. Apple’s second-quarter fiscal 2018 results benefited from growth in iPhone and Services segment.
The Services segment on the back of growing Apple Music & Apple Pay has become the new cash cow for the company. The higher ASP of iPhone X is boosting the top-line growth. Demand in China rebounded strongly driven by iPhone, Services, Mac and Watch sales.
Going forward, the Zacks analyst thinks Apple’s foray into fast-growing technologies like autonomous vehicle, artificial intelligence (AI) & AR/VR will drive growth. However, Apple faces significant competition in most of its operating markets. The rise of feature-rich regional smartphones at a much cheaper price remains a major headwind.
(You can read the full research report on Apple here >>>).
Shares of ExxonMobil have underperformed the Zacks Integrated Oil industry (-5.9% vs. +18.2%) as well as peer Chevron (+19.7%) over the last year. Exxon Mobil has a leading position in the energy industry owing to the size and diversity of its asset base, both in terms of business mix and geographical footprint. With a stable cash position, the company’s balance sheet is one of the best in the industry.
This has allowed Exxon to reward stockholders with 6.3% average annual dividend hike over the past 35 years. The Zacks analyst is optimistic about Canada’s Hebron project as the oil field has been backing Exxon’s upstream operations.
The company’s cost-control initiatives are impressive as reflected from 60% sequential reduction in exploration costs through first-quarter 2018. However, the company’s first-quarter earnings were lower than expected, thanks to decreased refinery throughput and lower margins at the chemical business.
(You can read the full research report on Visa here >>>).
Citigroup’s shares have underperformed the Zacks Major Banks industry over the last six months, losing -7.8% vs +1.3%. However, the company possesses an impressive earnings surprise history, beating expectations in all the trailing four quarters. The company’s first-quarter 2018 earnings reflected high revenues, along with loan growth. However, expenses escalated on ongoing investments.
The Zacks analyst thinks the company’s restructuring and streamlining efforts, strategic investments in core business, lower tax rate and expense management will likely support profitability. Expansion of wealth-management business in Australia will act as a tailwind.
Yet several issues, including litigation burden, keep us apprehensive. Also, despite rising rates, margin remains under pressure, due to persistent decline in the company’s legacy holdings portfolio.
(You can read the full research report on Citigroup here >>>).
Shares of Amgen have lost -2.6% year to date, outperforming the Zacks Biomedical and Genetics industry, which has declined -12% over the same period. Amgen beat expectations for both earnings and sales in 2018. Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Vectibix, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year.
However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands.
While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.
(You can read the full research report on Amgen here >>>).
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.